Mary Petrulis, MD
Neurology · Columbus, OHNPI 1578083614
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,438 of the $3,567 with a category attached, or 96.4%. Amgen accounts for 98.5% of it on its own, with 1 other manufacturer making up the rest.
Across 4 payments — averaging $891.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$55
Across 18 payments — averaging $10,242 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$172K
- Alnylam Pharmaceuticals Inc.$12K
What the payments were for
- Consulting fees$3,43896%
- Food & beverage$1304%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 3 | $3,513 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $55 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPLIZNA$3,438
How this compares
$3,567 in reported general payments places this provider in the 65th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mycophenolate Mofetil | 53 | $3,858 |
| Pyridostigmine Bromide | 54 | $2,838 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 16 | $1,929 |
| Gabapentin | 120 | $1,771 |
| Pregabalin | 43 | $1,764 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 16 | $873 |
| Duloxetine Hcl | 30 | $529 |
| Topiramate | 38 | $445 |
| Amitriptyline Hcl | 31 | $433 |
| Prednisone | 42 | $320 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 13 | $280 |
| Nortriptyline Hcl | 26 | $188 |
| Famotidine | 27 | $145 |
| Hydroxyzine Hcl | 12 | $137 |
| Tizanidine Hcl | 13 | $121 |
Paid to pharmacies, not to this prescriber.
Other neurology in Columbus
- Kenneth MankowskiColumbus$1.4M
- Aaron BosterColumbus$1.2M
- Jacqueline NicholasColumbus$743K
- Geoffrey EubankColumbus$508K
- Jerry MendellColumbus$315K
- Andrew SmithColumbus$254K
- Douglas ScharreColumbus$191K
- Aristide MerolaColumbus$133K
- Miriam FreimerColumbus$105K
- Allison JordanColumbus$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.